2024.02.22
On February 19, 2024, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, stock code: 02315.HK) announced an antibody evaluation and option agreement with Gilead Sciences, Inc. The agreement provides Gilead access to Biocytogen’s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.
Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead’s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and is committed to becoming a global headstream of new drugs. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery.
JunHe was engaged by Biocytogen to review, amend and negotiate the agreement. With its delivery of rigorous legal services and detail-oriented and professional expertise, JunHe’s team was highly trusted and recognized by the client.
The JunHe team was led by partner ZHAO, Hao (Gerry).
